Japanese department stores are expanding medical and beauty care services to take advantage of an increase in consumers wishing to avoid disease and stay healthy both inside and outside.
The stores aim to attract more shoppers through the face-to-face services, which are not possible online.
The antibody, administered intravenously every two weeks, is not a cure for the disease. An 18-month clinical trial involving about 1,800 patients showed that Alzheimer’s symptoms advanced 27 percent more slowly in those administered the medication than those who received a placebo, according to Eisai.
Eisai Co said Monday that it has applied for marketing authorization from Japan’s Pharmaceuticals and Medical Devices Agency for a new Alzheimer’s drug jointly developed with U.S. pharmaceutical company Biogen Inc.
Japanese drugmaker Eisai Co. and U.S. biopharmaceutical company Biogen Inc. said Wednesday an Alzheimer’s drug they are jointly developing has been found effective in slowing the deterioration of symptoms in a late-stage clinical trial.
Barrier Free Japan